Patient was not fit for Docetaxel therapy and he was put on monthly Denosumab injection 120 mg/1 syringe, and Abiraterone ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the ...

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate ...

American Oncology Institute (AOI) in collaboration with Nangia Specialty Hospital in Nagpur, has introduced the advanced Gallium generator marking a new chapter in precision medicine. It will enable ...

PSMA PET scans enable precise detection of prostate cancer even in its earliest stages, improving diagnostic accuracy and ...

Telix Pharma’s prostate cancer PET1 imaging agent, Illuccix receives European marketing approval: Melbourne, Australia Saturday, January 18, 2025, 10:00 Hrs [IST] Telix Pharmace ...

Telix Pharmaceuticals Limited today announces that it has received a positive decision on the Marketing Authorization ...

Over the coming months, it is anticipated Pluvicto will be available for eligible patients at most of Ontario’s Cancer ...

Over the coming months, it is anticipated Pluvicto will be available for eligible patients at most of Ontario’s Cancer ...

PSMA-PET/CT findings were positive in 84% of the patients. PSMA-PET/CT detected distant metastatic disease in 46% of patients, including 34% of patients after RP, 56% after definitive RT, and 60% ...